Gilead Sciences, Inc. (NASDAQ:GILD), reported first quarter non-GAAP EPS of $1.48 after the bell Tuesday, up from $0.48 a year ago. The consensus estimate was for EPS of $0.89. The stock is now up 3.05 on 2.7 million shares. Gilead Sciences, Inc. (NASDAQ:GILD), shares after opening at $72.86 moved to $73.26 on last trade day and at the end of the day closed at $72.86. Company price to sales ratio in past twelve months was calculated as 10.00 and price to cash ratio as 52.57. Gilead Sciences, Inc. (NASDAQ:GILD), showed a positive weekly performance of 9.09%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares gained 5.72% to $8.04. The company on Mar. 24 announced the initiation of a pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with crizotinib. The ALTA (ALK in Lung Cancer Trial of AP26113) trial is designed to determine the safety and efficacy of AP26113 in refractory NSCLC patients who test positive for the anaplastic lymphoma kinase (ALK+) oncogene. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), shares advanced 5.41% in last trading session and ended the day on $7.79. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), return on equity ratio is recorded as -98.50% and its return on assets is -65.80%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), yearly performance is -57.91%.
Geron Corporation (NASDAQ:GERN), an emerging competitor, is developing a telomerase inhibitor called Imetelstat in hematologic myeloid malignancies. Through internal efforts and potential future strategic partnerships, GERN is positioned to advance the commercialization of Imetelstat in one or more hematologic myeloid malignancies. The discovery and early development of Imetelstat was based on Geron’s core expertise in telomerase and telomere biology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless proliferation. Geron Corporation (NASDAQ:GERN), shares moved up 14.66% in last trading session and was closed at $2.19, while trading in range of $ 1.89 – 2.29. Geron Corporation (NASDAQ:GERN), year to date (YTD) performance is -53.80%.
VIVUS, Inc. (NASDAQ:VVUS), was downgraded by analysts at Piper Jaffray from a “neutral” rating to an “underweight” rating in a research report issued to clients and investors on Thursday, TheFlyOnTheWall.com reports. They currently have a $3.00 price objective on the stock, down from their previous price objective of $8.00. Piper Jaffray’s target price suggests a potential downside of 51.46% from the stock’s previous close. VIVUS, Inc. (NASDAQ:VVUS), weekly performance is 8.83%. On last trading day company shares ended up $5.30. VIVUS, Inc. (NASDAQ:VVUS), distance from 50-day simple moving average (SMA50) is -10.93%. Analysts mean target Price for the company is $8.11.
Leave a Reply